Clinical trial
Study of Forodesine Hydrochloride in Patients With Advanced…
NCT00289549 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00289549 |
|---|---|
| Title | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) |
| Official title | Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | forodesine hydrochloride (BCX-1777) |
| Enrollment | 8 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Feb 10, 2006 |
| Last update posted | Feb 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: